Clinical Trial

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer

Study acronym: PRIORITY
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 25, 2024 (before its estimated February 28, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective single-center, open-label, phase II study evaluating the efficacy of sintilimab plus anlotinib as a neoadjuvant regimen in the treatment of IB-IIIB resectable non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-13.
Trial Details
NCT Number NCT06221462
Lead Sponsor Ningbo No.2 Hospital
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 30 participants
Start Date 2024-02-01
Primary Completion 2025-02-28 (estimated)
Study Completion 2030-02-01 (estimated)
Updated on ClinicalTrials.gov 2024-01-25